Pearson v. Shalala
This article was originally published in The Tan Sheet
Executive Summary
FDA's deadline to appeal the D.C. federal appeals court decision to the Supreme Court expires June 30 without action by the agency. The appeals court required the agency to clarify the definition of its "significant scientific agreement" standard for health claims and to consider whether the four health claims at issue in the case might be deemed appropriate with the use of labeled "disclaimers." The four claims pertain to antioxidants, fiber, omega-3 fatty acids and folic acid (1"The Tan Sheet" Jan. 25, p. 3). The agency's request for a rehearing of the case was denied (2"The Tan Sheet" April 5, p. 7)
You may also be interested in...
WLF Ruling Could Invalidate DSHEA Restrictions, Attorney Says
Four of the five Dietary Supplement Health & Education Act restrictions on dissemination of third-party literature could constitute First Amendment violations under a federal judge's recent ruling on the distribution of off-label drug use studies, according to a D.C. attorney who represents dietary supplement makers.
WLF Ruling Could Invalidate DSHEA Restrictions, Attorney Says
Four of the five Dietary Supplement Health & Education Act restrictions on dissemination of third-party literature could constitute First Amendment violations under a federal judge's recent ruling on the distribution of off-label drug use studies, according to a D.C. attorney who represents dietary supplement makers.
WLF Ruling Could Invalidate DSHEA Restrictions, Attorney Says
Four of the five Dietary Supplement Health & Education Act restrictions on dissemination of third-party literature could constitute First Amendment violations under a federal judge's recent ruling on the distribution of off-label drug use studies, according to a D.C. attorney who represents dietary supplement makers.